Optiflow™
Nasal High Flow 
therapy

Proven* respiratory support

*A review of studies comprising the body of NHF evidence found the majority used F&P Optiflow™ systems

Videos of Optiflow NHF therapy in use

Therapy FAQs

Optiflow/Airvo products

Resources and downloads

Using Optiflow Nasal High Flow therapy to reduce the escalation of care for patients

High flow nasal cannula (HFNC), high flow therapy (HFT), high flow oxygen/therapy (HFO/T), nasal high flow (NHF), high flow nasal prongs (HFNP), high flow oxygen (HFO), humidified, high flow nasal cannula (HHFNC), heated, humidified high flow nasal cannula (HHHFNC), humidified high flow therapy (HHFT), nasal insufflation or just plain high flow (HF)

While many terms are used for this therapy, one name stands out as the way to deliver it.
Optiflow NHF therapy from Fisher & Paykel Healthcare is at the forefront of the field, featuring in
hundreds of publications and appearing in such prestigious journals as the NEJM and JAMA.
Using Optiflow NHF therapy as a first-line treatment (both pre-intubation and post-extubation) may reduce
a patient’s escalation “up the acuity curve”, resulting in better patient outcomes.

 

Nasal High Flow for primary support - Clinical Evidence

AHRF
 



“NHF may decrease the need for tracheal intubation"

~ Rochwerg et al, 2019.
Systematic review & Meta-analysis

AHRF (COVID-19)
 



“NHF may reduce the need for invasive ventilation and escalation of therapy "

~ Agarwal et al, 2020.
WHO-commissioned Systematic review & Meta-analysis

High risk patients
(post-operative)



“NHF likely prevents reintubation and escalation of therapy"

~ Chaudhuri et al, 2020.
Systematic review & Meta-analysis

Nasal High Flow post ventilation – Clinical Evidence 

Postextubation
 




“NHF reduces reintubation"

~ Granton et al, 2020.
Systematic review & Meta-analysis

Postextubation
(high risk patients)



“NHF with NIV significantly decreased the risk of reintubation"

~ Thille et al, 2019.
Randomized controlled trial
 

An interview with
Dr. Jean-Pierre Frat

Nasal High Flow (NHF) - Clinical research and clinical practice

Dr. Jean-Pierre Frat, chief investigator of the landmark FLORALI study, talks to us about his experience as a researcher and clinician, reflecting on a decade of using NHF. We discuss the practical application of NHF for multiple applications in Acute Hypoxemic Respiratory Failure.
 
Optiflow™ Nasal High Flow at the Royal Berkshire Hospital

Royal Berkshire Hospital (a multi-department implementation)

Optiflow NHF therapy at the Royal Berkshire Hospital. This video shows the usage of the F&P Airvo™ 2 Humidified High Flow System & Optiflow NHF therapy in different departments of the Royal Berkshire Hospital in Reading, UK. It shows the benefits they have found both to the patients and hospital since its introduction.

(3 minutes long)

Post-Extubation video

Extubating to
Optiflow NHF therapy

This video depicts extubation to Optiflow NHF therapy, and is based on the procedure used by Dr. Hernández and his colleagues' in the following studies:
Hernández et al. JAMA. 2016 (April) 1 and
Hernández et al. JAMA. 2016 (Oct.) 2 

Optiflow Nasal High Flow therapy newsletter - Flow Matters

Keep up to date with the latest in Optiflow Nasal High Flow therapy clinical research.

Flow Matters

Edition 11 (August 2020)

What systems and settings are used in NHF research?

Surveys of the studies comprising the body of NHF evidence found the majority used F&P Optiflow systems and flow settings between 45 and 60 L/min.
 
Read now Download PDF

Optiflow Nasal High Flow therapy -
frequently asked questions

FAQ speech box 1

Who does
Nasal High Flow
work on?

FAQ speech box 2

How quickly
does Nasal High
Flow work?

FAQ speech box 3

Is there a
protocol for
use of Nasal
High Flow?

FAQ speech box 4

Is there a bedside tool to predict the outcome of Nasal High Flow?

 
Take me to FAQs

 

ROX Index explained

Edition 9

(updated August 2020)
 
 
 




ROX* Index
Calculator
App
 
Use the ROX Index
Calculator App
to learn about
entering the
parameters
and calculating the
index.

 
 




ROX* Vector
App
 
Use the ROX
Vector App to learn
about visualizing trends
in the parameters
over time.


 
*Roca et al. Am J Respir Crit Care Med. 2019.

Optiflow technology

Fisher & Paykel Healthcare technology was the first choice for the important studies published
in NEJM and JAMA, securing the place of Optiflow technology at the forefront of this exciting therapy.

F&P AIRVO 2

Airvo 2 System

At a flow of 2 to 60 L/min, the Airvo 2 is a standalone nasal high flow system can be used across the entire care continuum, from the ED and the ICU to the floors and in the home.
 

Optiflow + Nasal Cannula

The Optiflow + Nasal Cannula originated from Fisher & Paykel Healthcare's dedication to improve care and outcomes. 
F&P MR850 Humidifier

MR850 System

The MR850 humidifier be used for the full range of Fisher & Paykel Healthcare therapies across the F&P Respiratory Care Continuum™.

Optiflow Nasal High Flow therapy Resources

Optiflow Cannula Fitting

F&P ROX index app

 
(Mobile App)
SHARE THIS TOOL
Optiflow Cannula Fitting

Frat et al FLORALI study infographic

(PDF)
SHARE THIS TOOL

 

Optiflow Cannula Fitting

Optiflow therapy brochure

 
(PDF 0.9MB)
Optiflow Cannula Fitting

Flow Matters 11

NHF system/settings in the evidence (PDF)
Optiflow Cannula Fitting

Flow Matters 10

COVID-19 edition (PDF)
Optiflow Cannula Fitting

Flow Matters 9

ROX Index edition (PDF)

References

Using Optiflow Nasal High Flow therapy to reduce the escalation of care for patients

 
View references


 

Optiflow Nasal High Flow

 
ENQUIRY FORM
 
 

If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.

   



   

 		  


   


Select your country of residence
   

   
 
   
Enter security code
 Security code
   
By submitting this form, you consent to Fisher & Paykel Healthcare storing your personal information to contact you about your enquiry. Your information will be collected and stored securely by Fisher & Paykel Healthcare Limited based in New Zealand and may be shared with the wider Fisher & Paykel Healthcare group as necessary to support your enquiry. We will not share, disclose or sell your information to third parties for marketing purposes. For full details on how we use and manage your personal information, how long we may retain this information for sales or marketing purposes, your rights to access, correct or delete your personal information, and how to contact us about your personal information, please see our privacy statement.
   
 
 

 

Want to receive updates?

Sign up to receive email notifications of the latest product and therapy information as well as upcoming events.
 

Sign up here

The outbreak of COVID-19 has impacted healthcare organizations around the world

A resource center has been created to provide affected hospitals and healthcare professionals with information they may need to treat patients when using Fisher & Paykel Healthcare products.
 

View resource center